Delos Wealth Advisors’s AbbVie ABBV Stock Holding History

Delos Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.6K	Buy	392 +192	+96%	+$41.3K	0.05%	105
2026 Q1	$43.5K	Sell	200 -10	-5%	-$2.22K	0.02%	131
2025 Q4	$48K	Hold	210	–	–	0.03%	95
2025 Q3	$48.6K	Hold	210	–	–	0.03%	105
2025 Q2	$39K	Buy	+210	New	+$39K	0.03%	104
2025 Q1	–	Sell	-3	Closed	-$611	–	54
2024 Q4	$611	Hold	3	–	–	﹤0.01%	185
2024 Q3	$672	Sell	3 -83	-97%	-$15.5K	﹤0.01%	166
2024 Q2	$14.8K	Sell	86 -8	-9%	-$1.32K	0.01%	109
2024 Q1	$17.2K	Buy	94 +83	+755%	+$14.3K	0.02%	99
2023 Q4	$1.73K	Sell	11 -424	-97%	-$61.8K	﹤0.01%	142
2023 Q3	$63.9K	Hold	435	–	–	0.08%	61
2023 Q2	$58.6K	Hold	435	–	–	0.07%	62
2023 Q1	$69.3K	Hold	435	–	–	0.09%	56
2022 Q4	$70.3K	Hold	435	–	–	0.11%	53
2022 Q3	$58K	Hold	435	–	–	0.07%	56
2022 Q2	$67K	Buy	435 +1	+0.2%	+$153	0.07%	53
2022 Q1	$70K	Hold	434	–	–	0.07%	68
2021 Q4	$59K	Buy	434 +424	+4,240%	+$50.1K	0.06%	69
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	160
2021 Q2	$1K	Buy	+10	New	+$1.13K	﹤0.01%	153

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Delos Wealth Advisors's ABBV Position: Q2 2026 in Review

Delos Wealth Advisors increased its AbbVie (ABBV) stake by 96% in Q2 2026, buying an estimated $41.3K and bringing the position to 392 shares worth $98.6K. The position accounts for 0.05% of the portfolio, ranked #105.

Delos Wealth Advisors first reported a position in ABBV in Q2 2021 and has held it in 20 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Delos Wealth Advisors held 392 shares of AbbVie worth $98.6K as of Q2 2026.
Delos Wealth Advisors bought 192 AbbVie shares in Q2 2026, an estimated $41.3K.
AbbVie made up 0.05% of Delos Wealth Advisors's portfolio in Q2 2026, its #105 holding.
Delos Wealth Advisors first reported a position in AbbVie in Q2 2021 and has held it in 20 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Delos Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.